White blood cell inactivation after treatment with riboflavin and ultraviolet light.
about
Improving platelet transfusion safety: biomedical and technical considerationsA pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia.A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial.Hemovigilance survey of pathogen-reduced blood components in the Warsaw Region in the 2009 to 2013 period.Pathogen reduction technologies: The pros and cons for platelet transfusion.Role of Riboflavin- and UV Light-Treated Plasma in Prevention of Transfusion-Related Acute Lung Injury.Component pathogen inactivation: a critical review.Trauma hemostasis and oxygenation research position paper on remote damage control resuscitation: definitions, current practice, and knowledge gapsPrimary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time.Alternative blood products and clinical needs in transfusion medicinePathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management.Developments in the prevention of transfusion-associated graft-versus-host disease.Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood.Riboflavin-ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells.Inactivation of Plasmodium falciparum in whole blood by riboflavin plus irradiation.GADD45α is involved in the apoptosis of lymphocytes induced by riboflavin and ultraviolet light.Pathogen reduction of whole blood: utility and feasibility.Treatment of buffy coat platelets in platelet additive solution with the mirasol(®) pathogen reduction technology system.The effectiveness of riboflavin and ultraviolet light pathogen reduction technology in eliminating Trypanosoma cruzi from leukoreduced whole blood.Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro.Response to: Evaluation of combined riboflavin and ultraviolet A as an alternative treatment for keratitis.FDA workshop on emerging infectious diseases: evaluating emerging infectious diseases (EIDs) for transfusion safety.Pathogen reduction by ultraviolet C light effectively inactivates human white blood cells in platelet products.Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease?Reduced alloimmunization in mice following repeated transfusion with pathogen-reduced platelets.Immune modulation and lack of alloimmunization following transfusion with pathogen-reduced platelets in mice.Treatment of platelets with riboflavin and ultraviolet light mediates complement activation and suppresses monocyte interleukin-12 production in whole blood.Functional inactivation of lymphocytes by methylene blue with visible light.Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process.
P2860
Q26775408-A69BDF05-3C61-4BEA-9EE4-A7BF27A79309Q33405052-8456514A-4CDF-4FA7-B74D-5607BDEA708BQ33429565-65A822BD-5CCB-44EB-B976-F8143EEC6A68Q33430920-7FDB73FC-4026-4FE2-A61D-539A5091267BQ33441980-8F6062FD-5E44-404F-B4C6-029EF6B8E083Q33863382-51057694-04B1-4A27-ABD5-3329018825BBQ34310415-DF2EAF58-3788-402B-AF3E-07F5DDD1972DQ35022509-BFD35B21-E116-4994-8340-175166DA91DDQ35064119-C9E71E3B-1EF7-4E06-A7D2-C837FBFEAB3EQ35915095-01DBFC15-38FD-4D0D-952F-73E1D14B43CDQ37903671-E671517B-89DE-4691-8750-36C908A47AFFQ37990036-904E22AE-E309-4590-9CD7-BAE7EA16D0CCQ38021811-229285FB-3C76-46B6-82A8-C4078192FA7AQ38794017-03090187-9D35-409B-9A36-1DA22E707114Q38934537-0CC2F657-01B5-45C6-B8BC-8AB395EA3B3EQ38984286-FE5293C2-7562-4617-9CDA-15A12470065FQ39140479-656A68DF-B50C-4F9D-953B-484559752E98Q40056466-C8641FEC-1317-46BF-A162-9F6BB76D3ECDQ40100501-78A8A642-2C62-4386-850E-9DB23CA306ACQ40246814-80FC33D1-5D83-40D1-ABC2-1CAA10E74B90Q42456722-0F118CF9-17F9-435C-B751-ED2D08DA9755Q43432121-D59B61A8-23E5-43C3-8BDC-9AECD362FA06Q44120840-81FF8810-786A-4349-B780-2BC5C7D891B4Q45136674-775A291D-7CF3-4063-A079-3B46CAC85A75Q46505820-AC68237A-D3AD-4F53-B338-D49537235A12Q46513449-FA6103F0-FB21-4088-868F-C987B41F709FQ46772168-6831AA6E-E307-45DC-B53A-3D795260ECDDQ47570271-870627DE-A2C6-40CD-8B4D-2784E4649859Q50210843-45C7AC56-2917-4363-801D-5CEBD03C46CBQ50536784-7EFDC078-86D3-4E8B-B534-258FF38F0DFC
P2860
White blood cell inactivation after treatment with riboflavin and ultraviolet light.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
White blood cell inactivation after treatment with riboflavin and ultraviolet light.
@en
White blood cell inactivation after treatment with riboflavin and ultraviolet light.
@nl
type
label
White blood cell inactivation after treatment with riboflavin and ultraviolet light.
@en
White blood cell inactivation after treatment with riboflavin and ultraviolet light.
@nl
prefLabel
White blood cell inactivation after treatment with riboflavin and ultraviolet light.
@en
White blood cell inactivation after treatment with riboflavin and ultraviolet light.
@nl
P2093
P1433
P1476
White blood cell inactivation after treatment with riboflavin and ultraviolet light.
@en
P2093
Loren D Fast
Raymond P Goodrich
Sherrill J Slichter
Susanne Marschner
William M Baldwin
P304
P356
10.1111/J.1537-2995.2010.02714.X
P577
2010-11-01T00:00:00Z